Esophageal Cancer: Diagnosis and Treatment
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Gastroenterology & Hepatopancreatobiliary Medicine".
Deadline for manuscript submissions: closed (28 March 2024) | Viewed by 1947
Special Issue Editor
Special Issue Information
Dear Colleagues,
Esophageal cancer is the sixth most common cause of cancer-related death worldwide, making it one of the most lethal gastrointestinal malignancies. There will be 21,560 patients diagnosed with esophageal cancer in the United States in the year 2023, and 16,120 patients will succumb to this disease. Esophageal cancer can be divided into two main histologic subtypes: adenocarcinoma and squamous cell carcinoma. While the squamous subtype remains the most prevalent, despite decreasing worldwide, the incidence of adenocarcinoma has continued to steadily and rapidly increase in developed, Western countries, even surpassing the prevalence of squamous cell carcinoma.
Despite improvements in surgical techniques, including minimally invasive and robotic approaches, as well as the development of adjuvant and neoadjuvant therapies, esophageal cancer has a dismal prognosis, with an overall 5-year survival rate of only 20 percent. Although advancements in the techniques of esophagectomy have shown a decrease in complications compared to the historical open approach, this operation is extremely complex and still carries significant risks of mortality and morbidity. The complication rate for esophagectomy has previously been reported as being between 17% and 74%.
Multimodal treatment plans consisting of combinations of chemotherapy, radiation, immunotherapy, and surgery are typically employed. Patients with locally advanced esophageal cancer will often undergo neoadjuvant therapy followed by surgery, which remains the gold standard of treatment. In this series we will focus on the critical aspects in the management of esophageal cancer, including systemic therapies, surgical techniques, and a review of post-operative outcomes.
Dr. Kenneth L. Meredith
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- esophageal cancer
- esophagectomy
- perioperative management
- systemic therapies
- neoadjuvant therapy
